Salarius Pharmaceuticals, Inc. (SLRX) is a leading innovative clinical-stage biotechnology company engaged in the development of cancer therapies for patients. Seclidemstat is the lead product candidate of the company in Phase 1/2 clinical trials. It is tried for the therapeutic potential for pediatric carcinoma prostrate, breast, ovarian cancers, and sarcomas.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
The price of SLRX stock during the regular trading on December 29, 2021, was $0.49 with a notable decrease of 6.19%. At last check in the aftermarket the stock recovered by 5.58%.
SLRX: Events and Happenings
On December 29, 2021, SLRX reported about the achievement of a dosing milestone in the Phase 1/2 clinical trial of Sarcoma assessing Seclidemstat therapeutic potential for Ewing sarcoma and further FET-rearranged sarcomas. The trial’ leads to the advanced second lead-in safety unit of treatment with seclidemstat at 900 mg BID.
On December 15, 2021, SLRX reported that the executives of the company presented at the Life Science Investor Forum held on December 16. On November 29, 2021, SLRX reported that the executives of the company presented at the Benchmark Company Discovery One-on-One Investor Conference held on December 2.
SLRX: Key Financials
On November 04, 2021, SLRX announced its financial highlights for the Q3 2021 ended September 30, 2021. Some of the important financial outcomes are as follows
Total Current Assets
Total current assets of the company for Q3 2021 were $35.18 million as compared to the assets of $13.9 million for the same period of 2020.
Net Loss per Share
Basic and diluted net loss reported by the company was $3.7 million, or $0.08 per share was reported for the third quarter of 2021, as compared to the same period of 2020 when it was $1.7 million, or $0.10 per share.
On October 07, 2021, SLRX reported the research findings from Virtual 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held on October 7-10. The outcomes showed that the SP-2577 potential activity in tumors was due to its different mechanism of action. On October 05, 2021, SLRX reported that company executives presented at the 2021 BioFuture Virtual Conference, held on October 5-6.
On September 28, 2021, SLRX reported the receipt of a $2.7 million payment with regard to its contract with the Cancer Prevention and Research Institute. The payment was used to support company operations and development of a lead drug, seclidemstat. On September 27, 2021, SLRX reported that the company executives presented at the Virtual Benzinga Healthcare Small-Cap Conference held on September 29-30. On September 22, 2021, SLRX reported about research collaboration with Cancer Epigenetics Institute.
Conclusion
The stock of SLRX is on a decline for the past month and a deceleration of 24% is observed from the past month. The investors are hoping that the stock will pick up the pace in the coming days.
